Evidence map›Paper›PMID 25807535›Full record

ArticlePloS one2015

Establishment of lal-/- myeloid lineage cell line that resembles myeloid-derived suppressive cells.

Xinchun Ding, Lingyan Wu, Cong Yan, Hong Du

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinchun DingDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States of America; IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States of America; The Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN, United States of America.
Lingyan WuDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States of America; IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States of America; The Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN, United States of America.
Cong YanDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States of America; IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States of America; The Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN, United States of America.
Hong DuDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States of America; IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States of America.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AMBER L. MOSLEY · 1999 to 2026
$59.3M
Pathophysiology of PPARgamma in the lungR01HL087001 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI DU, HONG · 2008 to 2012
$1.9M
Stat3 Downstream Genes as Lung Adenocarcinoma BiomarkersR01CA138759 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI YAN, CONG · 2010 to 2014
$1.8M
Inflammation and Immunosuppression in Lung CancerR01CA152099 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI YAN, CONG · 2011 to 2015
$1.5M
NCI NIH HHS CA138759NCI NIH HHS CA152099NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA138759NCI NIH HHS R01 CA152099NHLBI NIH HHS HL087001NHLBI NIH HHS R01 HL087001
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) in mouse are inflammatory cells that play critical roles in promoting cancer growth and metastasis by directly stimulating cancer cell proliferation and suppressing immune surveillance. In order to facilitate characterization of biochemical and cellular mechanisms of MDSCs, it is urgent to establish an "MDSC-like" cell line. By cross breeding of immortomouse (simian virus 40 large T antigen transgenic mice) with wild type and lysosomal acid lipase (LAL) knock-out (lal-/-) mice, we have established a wild type (HD1A) and a lal-/- (HD1B) myeloid cell lines. Compared with HD1A cells, HD1B cells demonstrated many characteristics similar to lal-/- MDSCs. HD1B cells exhibited increased lysosomes around perinuclear areas, dysfunction of mitochondria skewing toward fission structure, damaged membrane potential, and increased ROS production. HD1B cells showed increased glycolytic metabolism during blockage of fatty acid metabolism to fuel the energy need. Similar to lal-/- MDSCs, the mTOR signal pathway in HD1B cells is overly activated. Rapamycin treatment of HD1B cells reduced ROS production and restored the mitochondrial membrane potential. HD1B cells showed much stronger immunosuppression on CD4+ T cell proliferation and function in vitro, and enhanced cancer cells proliferation. Knockdown of mTOR with siRNA reduced the HD1B cell ability to immunosuppress T cells and stimulate cancer cell proliferation. Therefore, the HD1B myeloid cell line is an "MDSC-like" cell line that can be used as an alternative in vitro system to study how LAL controls various myeloid cell functions.

Indexed as

AnimalsCell ProliferationFatty AcidsImmunosuppression TherapyLysosomesMembrane Potential, MitochondrialMiceMice, KnockoutMyeloid CellsMyeloid Progenitor CellsReactive Oxygen SpeciesSignal TransductionFatty AcidsReactive Oxygen Species

Identifiers

PMID25807535
PMCPMC4373883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.